Switzerland-based Versantis AG has appointed Mark Fitzpatrick as its new chief executive, succeeding co-founder Vincent Forster who becomes chief scientific officer. Mr Fitzpatrick joins from Chiasma Inc, now part of Amryt Plc, where he was also CEO. At Versantis he will help advance the company’s lead product for acute-on-chronic liver failure which as received orphan designation in both the EU and the US.
Versantis announced the appointment on 20 December 2021.
Copyright 2022 Evernow Publishing Ltd